Seattle Genetics snags early approval for advanced breast cancer drugThe FDA has approved Seattle Genetics’ breast cancer drug Tukysa (tucatinib) four months early, including in certain patients Share XSeattle Genetics snags early approval for advanced breast cancer drughttps://pharmaphorum.com/news/fda-approves-seattle-genetics-advanced-breast-cancer-drug/
FDA sets August action date for Seattle’s oral HER2 drug tucatinibSeattle Genetics is a few months away from having its third drug product on the market, after the Share XFDA sets August action date for Seattle’s oral HER2 drug tucatinibhttps://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/
Seattle Genetics says data backs Padcev combo for first-line bladder cancerSeattle Genetics and Astellas’ new drug for relapsed bladder cancer – Padcev – could move up the treatment Share XSeattle Genetics says data backs Padcev combo for first-line bladder cancerhttps://pharmaphorum.com/news/seattle-genetics-says-data-backs-padcev-combo-for-first-line-bladder-cancer/
FDA backs Astellas/Seattle Genetics bladder cancer drugThe FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the Share XFDA backs Astellas/Seattle Genetics bladder cancer drughttps://pharmaphorum.com/news/fda-backs-astellas-seattle-genetics-bladder-cancer-drug/
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseaseAstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Share XAZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseasehttps://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Seattle Genetics plans to file breast cancer drug tucatinibSeattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in Share XSeattle Genetics plans to file breast cancer drug tucatinibhttps://pharmaphorum.com/news/seattle-genetics-plans-to-file-breast-cancer-drug/
FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drugThe FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder Share XFDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-astellas-seattle-genetics-bladder-cancer-drug/
Seattle Genetics and Astellas file bladder cancer drug in USSeattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced Share XSeattle Genetics and Astellas file bladder cancer drug in UShttps://pharmaphorum.com/news/seattle-genetics-and-astellas-file-bladder-cancer-drug-in-us/
